These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1730912)

  • 1. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1.
    Molina H; Wong W; Kinoshita T; Brenner C; Foley S; Holers VM
    J Exp Med; 1992 Jan; 175(1):121-9. PubMed ID: 1730912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand specificities of mouse complement receptor types 1 (CR1) and 2 (CR2) purified from spleen cells.
    Pramoonjago P; Takeda J; Kim YU; Inoue K; Kinoshita T
    Int Immunol; 1993 Apr; 5(4):337-43. PubMed ID: 7684250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of rat complement receptors and regulatory proteins. CR2 and Crry are conserved, and the C3b receptor of neutrophils and platelets is distinct from CR1.
    Quigg RJ; Holers VM
    J Immunol; 1995 Aug; 155(3):1481-8. PubMed ID: 7636211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of human CR1- and murine Crry-like exons in human CR2 transcripts due to CR2 gene mutations.
    Holguin MH; Kurtz CB; Parker CJ; Weis JJ; Weis JH
    J Immunol; 1990 Sep; 145(6):1776-81. PubMed ID: 2144008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2.
    Molina H; Kinoshita T; Webster CB; Holers VM
    J Immunol; 1994 Jul; 153(2):789-95. PubMed ID: 8021513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of C3-binding proteins on mouse neutrophils and platelets.
    Quigg RJ; Alexander JJ; Lo CF; Lim A; He C; Holers VM
    J Immunol; 1997 Sep; 159(5):2438-44. PubMed ID: 9278336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
    Carel JC; Frazier B; Ley TJ; Holers VM
    J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction.
    Molina H; Brenner C; Jacobi S; Gorka J; Carel JC; Kinoshita T; Holers VM
    J Biol Chem; 1991 Jul; 266(19):12173-9. PubMed ID: 1712014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative.
    Kinoshita T; Takeda J; Hong K; Kozono H; Sakai H; Inoue K
    J Immunol; 1988 May; 140(9):3066-72. PubMed ID: 2966205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
    Molina H; Perkins SJ; Guthridge J; Gorka J; Kinoshita T; Holers VM
    J Immunol; 1995 May; 154(10):5426-35. PubMed ID: 7730644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation.
    Foley S; Li B; Dehoff M; Molina H; Holers VM
    Eur J Immunol; 1993 Jun; 23(6):1381-4. PubMed ID: 8500531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.
    Klickstein LB; Bartow TJ; Miletic V; Rabson LD; Smith JA; Fearon DT
    J Exp Med; 1988 Nov; 168(5):1699-717. PubMed ID: 2972794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells.
    Fernández-Centeno E; de Ojeda G; Rojo JM; Portolés P
    J Immunol; 2000 May; 164(9):4533-42. PubMed ID: 10779754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extended multidomain solution structures of the complement protein Crry and its chimeric conjugate Crry-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy.
    Aslam M; Guthridge JM; Hack BK; Quigg RJ; Holers VM; Perkins SJ
    J Mol Biol; 2003 Jun; 329(3):525-50. PubMed ID: 12767833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands.
    Furtado PB; Huang CY; Ihyembe D; Hammond RA; Marsh HC; Perkins SJ
    J Mol Biol; 2008 Jan; 375(1):102-18. PubMed ID: 18028942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.
    Fridkis-Hareli M; Storek M; Or E; Altman R; Katti S; Sun F; Peng T; Hunter J; Johnson K; Wang Y; Lundberg AS; Mehta G; Banda NK; Michael Holers V
    Mol Immunol; 2019 Jan; 105():150-164. PubMed ID: 30513451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2.
    Molina H; Kinoshita T; Inoue K; Carel JC; Holers VM
    J Immunol; 1990 Nov; 145(9):2974-83. PubMed ID: 2145366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex.
    Tuveson DA; Ahearn JM; Matsumoto AK; Fearon DT
    J Exp Med; 1991 May; 173(5):1083-9. PubMed ID: 1708808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An allelic variant of Crry in the murine Sle1c lupus susceptibility interval is not impaired in its ability to regulate complement activation.
    Tchepeleva SN; Thurman JM; Ruff K; Perkins SJ; Morel L; Boackle SA
    J Immunol; 2010 Aug; 185(4):2331-9. PubMed ID: 20660348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.